-
Article
Open AccessCorrection: A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation
-
Article
Salvage lymphadenectomy in recurrent prostate cancer: is there evidence of real benefit?
Nodal recurrent prostate cancer (PCa) after primary radical treatment represents a heterogeneous entity with many treatment options. In some cases, surgical removal of metastatic nodes seems to improve cancer ...
-
Article
Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought
The goals of transurethral resection of a bladder tumor (TUR) are to completely resect the lesions and to make a correct diagnosis to adequately stage and treat the patient. Persistent disease after TUR is not...
-
Chapter
Adjuvant Treatment: Old and New Immunotherapy in Non-Muscle-Invasive Bladder Cancer
Bacillus Calmette-Guérin (BCG) is the first connection between bladder cancer and immunotherapy and still represents the gold standard treatment for intermediate and high-risk non-muscle-invasive bladder cance...
-
Article
Open AccessA novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation
Bruton’s tyrosine kinase (BTK) is essential for B-cell proliferation/differentiation and it is generally believed that its expression and function are limited to bone marrow-derived cells. Here, we report the ...
